Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 1
1954 1
1955 2
1956 1
1957 4
1958 2
1959 3
1961 1
1962 2
1964 4
1966 1
1967 2
1968 1
2004 1
2006 3
2007 2
2008 4
2009 4
2010 5
2011 7
2012 9
2013 8
2014 6
2015 4
2016 14
2017 13
2018 17
2019 11
2020 21
2021 25
2022 20
2023 29
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.
Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, Touzeau C, Leleu X, Moya N, Harel S, Perrot A, Bories P, Vincent L, Lamure S, Mohty M, Malard F, Manier S, Yakoub-Agha I, Schiano De Colella JM, Brisou G, Talbot A, Decaux O, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Moreau P, Arnulf B; Intergroupe Francophone du Myélome. Ferment B, et al. Among authors: houot r. Br J Haematol. 2024 May 15. doi: 10.1111/bjh.19505. Online ahead of print. Br J Haematol. 2024. PMID: 38747092
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Gutierrez FL, Menard C, Tarte K, Delfau MH, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F. Houot R, et al. Nat Med. 2024 May 14. doi: 10.1038/s41591-024-03053-z. Online ahead of print. Nat Med. 2024. PMID: 38745012 No abstract available.
High efficacy of CD19 CAR T-cells in patients with transformed Waldenström macroglobulinemia.
Durot E, Roosweil D, Chauchet A, Decroocq J, Di Blasi R, Gastinne T, Bensaber H, Cheminant M, Jacquet C, Guidez S, Gros FX, Bachy E, Coste A, Cony-Makhoul P, Treon SP, Delmer AJ, Reshef R, Le Gouill S, Castillo JJ, Houot R. Durot E, et al. Among authors: houot r. Blood. 2024 Apr 26:blood.2024024452. doi: 10.1182/blood.2024024452. Online ahead of print. Blood. 2024. PMID: 38669635
Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
Sarkozy C, Callanan MB, Thieblemont C, Obéric L, Burroni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griolet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue MH, Hermine O, Macintyre EA, Le Gouill S. Sarkozy C, et al. Among authors: houot r. Blood. 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944. Online ahead of print. Blood. 2024. PMID: 38669626
Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Crochet G, Iacoboni G, Couturier A, Bachy E, Iraola-Truchuelo J, Gastinne T, Cartron G, Fradon T, Lesne B, Kwon M, Gounot R, Martínez-Cibrian N, Castilla-Llorente C, Abrisqueta P, Guerreiro M, Sarkozy C, Aspa-Cilleruelo JM, Camus V, Guidez S, Chauchet A, Deconinck E, Bouabdallah K, Bosch F, Barba P, Morschhauser F, Houot R. Crochet G, et al. Among authors: houot r. Blood. 2024 Apr 24:blood.2024024526. doi: 10.1182/blood.2024024526. Online ahead of print. Blood. 2024. PMID: 38657242
CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.
Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, Waultier-Rascalou A, di Blasi R, Houot R, Souchet L, Roos-Weil D, Uzunov M, Quoc SN, Jacque N, Boussen I, Gauthier N, Ouzegdouh M, Blonski M, Campidelli A, Ahle G, Guffroy B, Willems L, Corvilain E, Barrie M, Alcantara M, le Garff-Tavernier M, Psimaras D, Weiss N, Baron M, Bravetti C, Hoang-Xuan K, Davi F, Shor N, Alentorn A, Houillier C. Choquet S, et al. Among authors: houot r. Am J Hematol. 2024 Apr 8. doi: 10.1002/ajh.27316. Online ahead of print. Am J Hematol. 2024. PMID: 38586986
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Stathis A, Pirosa MC, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FG, Merli F, Guièze R, Gyan E, Gini G, Marino D, Gressin R, Morschhauser F, Cavallo F, Palombi F, Conconi A, Tessoulin B, Tilly H, Zanni M, Cabras MG, Capochiani E, Califano C, Celli M, Pulsoni A, Angrilli F, Occhini U, Casasnovas RO, Cartron G, Devizzi L, Haioun C, Liberati AM, Houot R, Merli M, Pietrantuono G, Re F, Spina M, Landi F, Cavalli F, Bertoni F, Rossi D, Ielmini N, Borgo E, Luminari S, Zucca E, Thieblemont C. Stathis A, et al. Among authors: houot r. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283918. Online ahead of print. Haematologica. 2024. PMID: 38385243 Free article.
214 results